Laura Soucek, a former In Vivo Rising Leader, and her co-founder have built their biotech, Peptomyc, around a previously undruggable target. They spoke about successes and learnings as scientist-entrepreneurs at BioEurope Spring.
The last time In Vivo spoke with 2020 Rising Leader Laura Soucek about Peptomyc S.L., the Barcelona-based biotech she co-founded and is CEO of, she was preparing to start a Phase I trial for the company’s lead Myc inhibitor, OMO-103. [A# IV124628]
At the time, the story was that she was pushing up against established dogma. Myc was undruggable, according to most...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.
As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
